Clinical trials: SARS
Healthy, Immunization; Infection
BNT162b2 Vaccination With 2 Doses in COVID-19 Negative Volunteers and With a Single Dose in COVID-19 Positive Volunteers
As previously shown, individuals who experienced COVID-19 have developed some protective immunity to reinfection. The magnitude and duration of protection from reinfection conferred by the infection may be weaker after an…
- Trial name
- CoviCompareP (NCT04824638)
- Testing
- 3 doses of BNT162b2 vaccine, 2 dose of BNT162b2 vaccine
- Where
- 11 sites in France
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
SARS-CoV-2, COVID-19
A Study of the Effectiveness of Moderna COVID-19 Vaccine
This is an observational cohort study to evaluate real-world vaccine effectiveness and durability of Moderna COVID-19 vaccine among a diverse population at Kaiser Permanente Southern California (KPSC).
- Trial name
- NCT05933304
- Where
- United States
- Volunteers
- 927,004 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID-19
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study…
- Trial name
- NCT04760730
- Testing
- AZD1222, rAd26-S
- Where
- United Arab Emirates
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Infection by SARS-COV-2, Healthy Controls
Detection of Asymptomatic SARS-Cov2 Infected Patients by Detection Dogs: "Proof of Concept" Study (CoviDetectionDog)-Covid-19
The spread of the new SARS-CoV-2 virus has led to a pandemic. Described for the first time in China at the end of 2019, it causes Covid-19 disease.
- Trial name
- NCT04970563
- Testing
- Body odor samples
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Hôpital Européen Marseille
Pneumonia, Community-Acquired, COVID-19 Pneumonia
Cardiovascular Disease Progression in Survivors of Community Acquired Pneumonia and Lung Infection by Covid-19.
Pneumonia, which can be acquired in the community (including influenza and COVID-19), is a leading cause of mortality. The risk of severe cardiovascular diseases events (stroke, myocardial infarction, pulmonary embolism)…
- Conditions
- Pneumonia, Community-Acquired, COVID-19 Pneumonia, Cardiovascular Diseases
- Trial name
- HOMI-LUNG CAP (NCT06601998)
- Testing
- Blood samples and Oropharyngeal swab, Six-minute walk test, Spirometry, ECG, Heart ultrasound and cardiopulmonary exercise stress testing, Completion of questionnaires of symptoms
- Where
- 18 sites in Greece
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- Hellenic Institute for the Study of Sepsis
COVID-19
A Randomised, Multi-centre, Double-blind, Phase 3 Study to Observe the Effectiveness, Safety and Tolerability of Molnupiravir Compared to Placebo Administered Orally to High-risk Adult Outpatients With Mild COVID-19 Receiving Local Standard of Care in South Africa
This is a multi-centre, double-blind, phase 3 study to observe the effectiveness, safety, and tolerability of molnupiravir 800 mg administered 12-hourly for five days in adult patients with mild COVID-19 at the time of enrolment…
- Trial name
- CoTeT (NCT05459532)
- Testing
- Molnupiravir 200 mg
- Where
- 4 sites in South Africa
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- University of Witwatersrand, South Africa
COVID-19, Pneumonia, Viral
Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and Death
Since late December 2019, the novel human coronavirus (SARS-CoV-2) first reported in China, has spread worldwide. Vaccines to prevent SARS-CoV-2 infections have been developed in record time and several candidate vaccines have…
- Trial name
- NCT04914832
- Testing
- AZD1222
- Where
- Eswatini
- Volunteers
- 75,012 people, healthy volunteers welcome
- Sponsor
- Shabir Madhi
Sickle Cell Disease
Severe Acute Respiratory Syndrome CoV 2 COVID-19 Survey and Vaccination Coverage in the Sickle Cell Population in Ile-De-France
The objective of this study is to determine the seroprevalence of severe acute respiratory syndrome-CoV-2 in unvaccinated sickle cell patients living in an area with high viral circulation and at risk of high viral transmission…
- Trial name
- COVIDO-DREP (NCT05153044)
- Testing
- severe acute respiratory syndrome CoV-2 serology
- Volunteers
- 880 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
SARS-CoV Infection, Immune System Disorder
Co-Sér: Serological Analysis and Viral Neutralization in People With a Documented COVID-19 Infection
In light of the current coronavirus disease 2019 (COVID-19) pandemic, the investigators want to better study the immunological characteristics of Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV2) infections in adults.
- Trial name
- Coser (NCT05000307)
- Testing
- Blood sample
- Where
- Belgium
- Volunteers
- 79 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Sars-CoV2
Prevalence of COVID-19 Infection Among HCW in a French University Hospital
The objective of this study is to determine the prevalence of SARS-Cov2 infection among health care workers exposed of Lille University Hospital, to describe its evolution during the epidemic taking into account the influence of…
- Trial name
- EXPOCOVIA (NCT04371692)
- Testing
- self-administered questionnaire, SARS-Cov2 testing
- Where
- France
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
SARS-CoV-2
Impact of SARS-CoV-2 Pandemic on Psychological State of Health Care Workers
In COVID-19 pandemic, many health-care workers (HCWs) have worked in high-pressure environments. They have been exposed to and faced moral dilemmas in addition to infection exposure risk are increasing the risk of mental health…
- Trial name
- NCT04779944
- Testing
- other
- Where
- Egypt
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Assiut University
SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV)
Transplacental Transmission of RSV (TTRSV)
Aim 1: To study transplacental transmission of Respiratory Syncytial Virus (RSV) and how this is moderated by other maternal infections during pregnancy Aim 2: To test maternal blood for presence of RSV-specific immunoglobulins…
- Conditions
- SARS CoV 2 Infection, Respiratory Syncytial Virus (RSV), Bronchiolitis, Asthma
- Trial name
- NCT05443607
- Where
- 2 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Tulane University
SARS-Cov2
SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Since the beginning of the year, the entire world has been concerned with the novel SARS-CoV2 virus. After the first case descriptions in Wuhan, there has been a rapid increase in the number of cases in Germany as well.
- Trial name
- SARS-CoV2_KIDS (NCT04581148)
- Testing
- Blood test antibodies against SARS-CoV-2
- Where
- Germany
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
SARS-CoV-2
A Global Multi-center Clinical Study of SARS-CoV-2 mRNA Vaccine for the Prevention of COVID-19
A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged…
- Trial name
- NCT05682638
- Testing
- LVRNA009, 0.9%NaCl
- Where
- Kenya
- Volunteers
- 34,000 people, healthy volunteers welcome
- Sponsor
- AIM Vaccine Co., Ltd.
Sars-CoV2, Infection Viral
HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers
Background: Aim: To demonstrate the efficacy of low-dose hydroxychloroquine as primary prevention in healthcare workers Design, participants and interventions: Prospective, randomized, parallel group, double-blinded, placebo…
- Conditions
- Sars-CoV2, Infection Viral, Healthcare Worker, Prophylaxis
- Trial name
- NCT04336748
- Testing
- Hydroxychloroquine
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical University of Vienna
SARS-CoV 2, COVID-19
Assessment of the Psycho-social Impact of COVID-19 Outbreak
It has been shown in previous important outbreaks of infectious diseases that they have a huge impact on individuals and communities.
- Conditions
- SARS-CoV 2, COVID-19, Quality of Life, Mental Health Wellness 1
- Trial name
- COM-COVID (NCT04378452)
- Testing
- COM-COVID anonimous survey
- Where
- 4 sites in Spain
- Volunteers
- 56,656 people, healthy volunteers welcome
- Sponsor
- Fundació Institut Germans Trias i Pujol
COVID-19, Severe Acute Respiratory Syndrome
Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial)
Triple blinded, phase III randomized controlled trial with parallel groups (200mg of hydroxychloroquine per day vs. placebo) aiming to prove hydroxychloroquine's security and efficacy as prophylaxis treatment for healthcare…
- Trial name
- PHYDRA (NCT04318015)
- Testing
- Hydroxychloroquine
- Where
- Mexico
- Volunteers
- 289 people, healthy volunteers welcome
- Sponsor
- National Institute of Respiratory Diseases, Mexico
Healthy
A Trial to Learn if a COVID-19 Therapeutic is Safe and Well Tolerated, and How it Works in the Body of Healthy Adult Participants
The primary objective of the study is to evaluate the safety and tolerability of REGN14284 in healthy participants, as measured by all treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events…
- Trial name
- NCT05505448
- Testing
- REGN14284
- Where
- Belgium
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Regeneron Pharmaceuticals
SARS-CoV2 Infection
Qualitative and Functional Investigation of Lipids in Patients With SARS-CoV2 Infection - In Search of Atherogenic Sequelae
Currently, the world is facing a SARS-CoV2 coronavirus epidemic, which is responsible for COVID-19. In France, this virus has already infected several million people and is responsible for the death of more than 127,000.
- Trial name
- COVI-LIPI-D (NCT05476224)
- Testing
- Blood sample of 30 ml
- Where
- France
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
COVID-19
Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study are: To describe the safety profile of all participants in each age group and each study intervention group up to 12 months post-last dose.
- Trial name
- VAW00001 (NCT04798027)
- Testing
- SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 182 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.